drugset / Trial / NCT01552928
Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers
RandomizedCrossoverQuadruple-blindTreatment
Summary
According to the ICH Guidance Document E14, all non-antiarrhythmic drugs should be evaluated for their ability to prolong the QT interval which represents the duration of ventricular depolarization and subsequent repolarization. The primary objective of the study is to assess the effect of anagrelide on QT/QTc interval following a therapeutic and supratherapeutic dose of anagrelide when compared to placebo and a positive control.
Timeline
- Start
- 2012-03-29
- Primary completion
- 2012-07-25
- Completion
- 2012-07-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anagrelide | Small molecule | 0.5 mg | Oral |
| Subject | Anagrelide | Small molecule | 2.5 mg | Oral |
| Comparator | Moxifloxacin | Small molecule | 400 mg | Oral |
Indications
No indication recorded.